The present invention is to provide a means for enhancing skeletal muscle. According to the present invention, the skeletal muscle is enhanced by using spermidine or a pharmaceutically acceptable salt thereof is administered intramuscularly as an active ingredient.
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
[wherein —X═ represents —CH═ or the like; ═Y— represents ═CH— or the like; R1 and R2 each independently represent a hydrogen atom or the like; R3 represents a hydrogen atom or the like; and Z is a group represented by Formula (II):
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
[wherein —X═ represents —CH═ or the like; ═Y— represents ═CH— or the like; R1 and R2 each independently represent a hydrogen atom or the like; R3 represents a hydrogen atom or the like; and Z is a group represented by Formula (II):
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
[wherein —X═ represents —CH═ or the like; ═Y— represents ═CH— or the like; R1 and R2 each independently represent a hydrogen atom or the like; R3 represents a hydrogen atom or the like; and Z is a group represented by Formula (II):
(wherein the wavy line represents the point of attachment to the nitrogen atom; ring Z1 represents a C6-10 aryl group or the like; m represents 0, 1, or 2; and R4 represents a halogen atom or the like.) or Formula (III):
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
[wherein —X═ represents —CH═ or the like; ═Y— represents ═CH— or the like; R1 and R2 each independently represent a hydrogen atom or the like; R3 represents a hydrogen atom or the like; and Z is a group represented by Formula (II):
(wherein the wavy line represents the point of attachment to the nitrogen atom; ring Z1 represents a C6-10 aryl group or the like; m represents 0, 1, or 2; and R4 represents a halogen atom or the like.) or Formula (III):
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
[wherein —X═ represents —CH═ or the like; ═Y— represents ═CH— or the like; R1 and R2 each independently represent a hydrogen atom or the like; R3 represents a hydrogen atom or the like; and Z is a group represented by Formula (II):
(wherein the wavy line represents the point of attachment to the nitrogen atom; ring Z1 represents a C6-10 aryl group or the like; m represents 0, 1, or 2; and R4 represents a halogen atom or the like.) or Formula (III):
(wherein the wavy line represents the point of attachment to the nitrogen atom; ring Z2 represents a C6-10 aryl group or the like; L represents a single bond or the like; ring Z3 represents a C6-10 aryl group or the like; n represents 0, 1, or 2; and R5 represents a halogen atom or the like.]
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Cosmetics; cosmetic preparations; cosmetic lotions; cosmetic
creams; cosmetic gels; facial emulsions; dentifrices;
mouthwash, not for medical purposes; non-medicated dental
rinses. Pharmaceuticals; pharmaceutical preparations; preparations
for treating colds; cough treatment preparations; anti-cough
drops; pastilles for pharmaceutical purposes. Medical apparatus and instruments; chemically activated cold
gel packs for medical purposes; cooling patches for medical
purposes; cooling pads for first aid purposes.
The purpose of the present invention is to provide: a composition for treating acute rhinitis and allergic rhinitis: and a method for treating acute rhinitis and allergic rhinitis. Specifically, the present invention pertains to a composition that comprises, per 100 mL of the composition, chlorpheniramine or a pharmaceutically acceptable salt thereof in an amount of 200-1000 mg as expressed in terms of chlorpheniramine maleate, and oxymetazoline or a pharmaceutically acceptable salt thereof in an amount of 10-100 mg as expressed in terms of oxymetazoline hydrochloride; and a method for treating acute rhinitis and allergic rhinitis by spraying the composition into a nostril once a day or twice a per day at an interval of 10 hours or more.
An application container (1) of the present invention includes: an inner plug member (20) mounted on a mouth portion (10) of a container main body (2) and formed with a communication hole (21) and a discharge hole (22); a holder (30) that includes an accommodating portion (31) and a plug body (35) and is formed with a communication path (40) between the holder (30) and the inner plug member (20); an application member (50) disposed in the accommodating portion (31); a biasing member (60) configured to bias the holder (30) upward with respect to the inner plug member (20); an overcap (4) mounted on the mouth portion (10) of the container main body (2); and a seal portion (80) configured to block communication between the communication path (40) and an outside, in a state where the overcap (4) is removed from the mouth portion (10) and the plug body (35) closes the communication hole (21).
The present invention is to provide a means for promoting muscle regeneration from muscle damage.
The present invention is to provide a means for promoting muscle regeneration from muscle damage.
According to the present invention, the muscle regeneration from muscle damage is promoted by using a compound having histamine H receptor agonist activity (except for histamine) or a salt thereof is used as an active ingredient.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
10 - Medical apparatus and instruments
Goods & Services
(1) Cosmetics; cosmetic creams, milks, lotions, gels and powders for the face, hands and body; facial emulsions; non-medicated dentifrices; non-medicated toothpastes; non-medicated mouthwashes and gargles.
(2) Chemically activated cold gel packs for medical purposes; cooling patches for medical purposes; cooling pads for first aid purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Anti-aging vitamin supplements; coenzyme q10 dietary supplements; dietary and nutritional supplements for general health and well being; dietary and nutritional supplements used for energy stimulation; dietary supplements consisting of vitamins; liquid vitamin supplements; nutritional supplement drink mixes and powders for general health and well-being; nutritional supplements consisting of vitamins and minerals; vitamin supplements
(2) Multi-vitamin supplements
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Anti-perspirants and deodorants for personal use; beauty soaps; cleansing and moisturizing creams, oils and lotions; cosmetic make-up remover; cosmetic preparations for moisturizing, firming, reducing the appearance of cellulite, smoothing, and conditioning the skin; cosmetic preparations for skincare; cosmetic soaps; cosmetic sunscreen preparations; cosmetics; face and body creams for cosmetic purposes; facial emulsions for cosmetic purposes; facial serums for cosmetic purposes; facial soaps; gargles; hair care creams for cosmetic purposes; lip creams for cosmetic purposes; liquid soaps for hands, face and body; lotions for cosmetic purposes; mask packs for cosmetic purposes; milk for cosmetic purposes; non-medicated dentifrices; non-medicated mouthwashes; non-medicated toothpastes; sheet face masks for cosmetic purposes; skin cleansing gels; skin soaps; tooth gel; tooth whitening gels
(2) Analgesics; anti-cough drops; anti-inflammatory preparations; antibacterials; antifungal preparations; athlete's foot preparations; cough pastilles for medical use; cough treatment preparations; decongestant nasal sprays; dietary and nutritional supplements for general health and well being; dietary and nutritional supplements used for energy stimulation; dietary supplement drinks for general health and well being; eye drops; laxatives; medicated nasal spray preparations; medicines for the treatment of gastrointestinal diseases; motion sickness medicines; motion sickness treatment preparations; nasal drops for the treatment of allergies; nose drops for medical purposes; nutritional supplement drink mixes and powders for general health and well-being; oral analgesics; pharmaceutical preparations for the treatment of chronic rhino sinusitis with nasal polyps; plasters for medical purposes; poultices; preparations for the relief of pain; topical analgesics; vitamin supplements
(3) Medicated plasters for use in the treatment of muscle pain, joint pain, backache, arthritis, strains, brises and sprains; medicated lotions for the relief of backaches, muscular aches and pains; multi-vitamin supplements; topical preparations, namely, sprays for the relief of pain; pharmaceutical preparations for treating skin disorders; anti-itch ointment, jelly, or cream; preparations for treating colds in the form of tablets, capsules or syrups; medicated throat sprays to prevent swelling in throats;
(4) Chemically activated cold gel packs for medical purposes; cooling packs for therapeutic purposes; cooling patches for medical purposes
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
(1) Beauty soaps; cleansing and moisturizing creams, oils and lotions; cosmetic make-up remover; cosmetic preparations for moisturizing, firming, reducing the appearance of cellulite, smoothing, and conditioning the skin; cosmetic preparations for skincare; cosmetic soaps; cosmetic sunscreen preparations; cosmetics; face and body creams for cosmetic purposes; facial emulsions for cosmetic purposes; facial serums for cosmetic purposes; facial soaps; hair care creams for cosmetic purposes; lip creams for cosmetic purposes; liquid soaps for hands, face and body; lotions for cosmetic purposes; mask packs for cosmetic purposes; milk for cosmetic purposes; non-medicated dentifrices; non-medicated mouthwashes; non-medicated toothpastes; sheet face masks for cosmetic purposes; skin cleansing gels; skin soaps; tooth gel; tooth whitening gels
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
(1) Anti-perspirants and deodorants for personal use; beauty soaps; cleansing and moisturizing creams, oils and lotions; cosmetic make-up remover; cosmetic preparations for moisturizing, firming, reducing the appearance of cellulite, smoothing, and conditioning the skin; cosmetic preparations for skincare; cosmetic soaps; cosmetic sunscreen preparations; cosmetics; face and body creams for cosmetic purposes; facial emulsions for cosmetic purposes; facial serums for cosmetic purposes; facial soaps; hair care creams for cosmetic purposes; lip creams for cosmetic purposes; liquid soaps for hands, face and body; lotions for cosmetic purposes; mask packs for cosmetic purposes; milk for cosmetic purposes; non-medicated dentifrices; non-medicated mouthwashes; non-medicated toothpastes; sheet face masks for cosmetic purposes; skin cleansing gels; skin soaps; tooth gel; tooth whitening gels
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
(1) Beauty soaps; cleansing and moisturizing creams, oils and lotions; cosmetic make-up remover; cosmetic preparations for moisturizing, firming, reducing the appearance of cellulite, smoothing, and conditioning the skin; cosmetic preparations for skincare; cosmetic soaps; cosmetic sunscreen preparations; cosmetics; face and body creams for cosmetic purposes; facial emulsions for cosmetic purposes; facial serums for cosmetic purposes; facial soaps; hair care creams for cosmetic purposes; lip creams for cosmetic purposes; liquid soaps for hands, face and body; lotions for cosmetic purposes; mask packs for cosmetic purposes; milk for cosmetic purposes; non-medicated dentifrices; non-medicated mouthwashes; non-medicated toothpastes; sheet face masks for cosmetic purposes; skin cleansing gels; skin soaps; tooth gel; tooth whitening gels
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Poultices; adhesive plasters for medical purposes; medical plasters for temporary relief of backaches, muscular aches and pains; medicated lotions for the relief of backaches, muscular aches and pains; medicated creams for the relief of backaches, muscular aches and pains; medicated sprays for the relief of backaches, muscular aches and pains
The purpose of the present invention is to provide: a composition for treating acute rhinitis and allergic rhinitis; use of the same; and a method for treating acute rhinitis and allergic rhinitis. Specifically, the present invention pertains to a composition that contains, per 100 mL of the composition, chlorpheniramine or a pharmaceutically acceptable salt thereof in an amount of 200-1000 mg as expressed in terms of chlorpheniramine maleate, and oxymetazoline or a pharmaceutically acceptable salt thereof in an amount of 10-100 mg as expressed in terms of oxymetazoline hydrochloride, and that is for treating acute rhinitis and allergic rhinitis by spraying the same into the nostrils once per day or twice per day at an interval of 10 hours or more.
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
[wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom and the like, R3 represents a hydrogen atom and the like, R4 represents a hydrogen atom and the like, R5 represents a hydrogen atom and the like, W represents an oxygen atom and the like, and X represents a C1-6 alkyl group and the like.]
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
The present invention provides a means for enhancing skeletal muscles. Specifically, spermidine or a pharmaceutically acceptable salt thereof is intramuscularly administered as an active ingredient.
The present invention provides: a compound that has an inhibitory action against hematopoietic prostaglandin D synthase (H-PGDS), and thus is useful for the prevention and treatment of diseases in which the enzyme is involved; and a pharmaceutical composition that contains said compound. Specifically, provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, −X= represents −CH= or the like; =Y− represents =CH− or the like; R1and R2each independently represent a hydrogen atom or the like; R3represents a hydrogen atom or the like; Z is a group represented by formula (II): (in the formula, the wavy line indicates the point of bonding to the nitrogen atom; ring Z16-106-10 aryl group or the like; m represents 0, 1 or 2; R4represents a halogen atom or the like) or by formula (III): (in the formula, the wavy line indicates the point of bonding to the nitrogen atom; ring Z26-106-10 aryl group or the like; L represents a single bond or the like; ring Z36-106-10 aryl group or the like; n represents 0, 1 or 2; R5 represents a halogen atom or the like).]
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nasal sprays for medical purposes; nasal drops for the treatment of allergies; decongestant nasal sprays; nasal cleaning preparations for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nasal sprays for medical purposes; nasal drops for the treatment of allergies; decongestant nasal sprays; nasal cleaning preparations for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Decongestant nasal sprays; medicated nasal spray preparations; nasal drops for the treatment of allergies; nose drops for medical purposes; pharmaceutical preparations for the treatment of chronic rhino sinusitis with nasal polyps
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Decongestant nasal sprays; medicated nasal spray preparations; nasal drops for the treatment of allergies; nose drops for medical purposes; pharmaceutical preparations for the treatment of chronic rhino sinusitis with nasal polyps
The present invention provides an application container (1) provided with: an inside plug member (20) that is attached to a mouth part (10) of a container body (2) and has a communication hole (21) and an ejection hole (22) formed therein; a holder (30) that has an accommodation part (31) and a plug body (35) and has a communication path (40) formed between the holder (30) and the inside plug member (20); an application member (50) that is arranged inside the accommodation part (31); a biasing member (60) that biases the holder (30) upward with respect to the inside plug member (20); an over-cap (4) that is attached to the mouth part (10) of the container body (2); and a seal part (80) that intercepts communication between the communication path (40) and the outside in a state in which the over-cap (4) is detached from the mouth part (10) and the plug body (35) closes the communication hole (21).
The present invention is to provide a means for promoting muscle regeneration from muscle damage.
The present invention is to provide a means for promoting muscle regeneration from muscle damage.
According to the present invention, the muscle regeneration from muscle damage is promoted by using a compound having 5-HT2B receptor agonist activity or a salt thereof is used as an active ingredient.
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The present invention provides: compounds that have an inhibitory activity on hematopoietic prostaglandin D synthase (H-PGDS) and are useful for the prevention or treatment of diseases in which the synthase is implicated; and drug compositions that contain the compounds. In specific terms, the present invention provides compounds given by formula (I) or a pharmaceutically acceptable salt thereof. [In formula (I), R1represents a hydrogen atom, etc.; R2represents a hydrogen atom, etc.; R3represents a hydrogen atom, etc.; R4represents a hydrogen atom, etc.; R51-61-6 alkyl group, etc.]
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
222n22OH (in the formula, n represents an integer) and having an average molecular weight of 380-420, ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
45.
Pharmaceutical composition containing antifungal agent as active ingredient
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
47.
Primer set for detecting trichophyton gene by lamp method, kit including same, and method for detecting trichophyton using same
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
The present invention provides a method for producing a difluoromethylene compound and an intermediate thereof, which are useful in the field of pharmaceuticals.
Specifically provided is a method for producing a difluoromethylene compound, including a step of allowing a compound represented by formula (6):
1 represents a lower alkyl group, a halogen atom, a halo-lower alkyl group, a cycloalkyl group, a cyano group, or a hydroxy lower alkyl group; and W represents a nitrogen atom or a methine group] to react with a compound represented by formula (7):
3 represents a chlorine atom, a bromine atom, or an iodine atom].
The present invention is provided with a container body (2), an inner plug member (20), and an impregnation material (30). The inner plug member (20) is provided with: an impregnation-member-accommodating part (21); and a valve-body-accommodating part (22) having a valve seat (22a) on the impregnation-member-accommodating-part (21) side and a valve body support part (22b) on the container-body (2) side, there being a valve body (22c) movably installed between the valve seat (22a) and the valve body support part (22b). In a state in which the valve body (22c) is supported by the valve body support part (22b), a communication groove (50) that forms a gap is formed between the valve body (22c) and the valve-body-accommodating part (22).
The purpose of the present invention is to provide a method for diagnosing tinea simply and rapidly, a method for detecting trichophyton, or a method for detecting a trichophyton gene. Using at least four types of specific primers designed on the basis of a DNA sequence of a trichophyton gene can simply and rapidly detect said trichophyton gene by means of a LAMP method.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
22-adrenergic receptor antagonist activity and carbonic anhydrase-inhibitory activity, and that exhibits excellent ocular antihypertensive activity. Specifically provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, A represents an optionally substituted phenyl group, etc. R1and R2each independently represent a hydrogen atom, etc. X1represents a single bond, etc. X2represents a single bond, etc. B denotes formula (AA) or formula (BB) (where W1represents a nitrogen atom, etc.; W2represents an oxygen atom, etc.; W3represents a nitrogen atom, etc.; Rb1represents an optionally substituted phenyl group, etc.; and Rb2 represents a hydrogen atom, etc.)]
C07C 311/37 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides a method for producing a difluoromethylene compound useful in the field of pharmaceuticals and for producing an intermediate of the compound. Specifically, the present invention provides a method for producing a difluoromethylene compound, the method including the step of reacting a compound represented by formula (6) with a compound represented by formula (7). [In formula (6), L1 represents a halogen atom or a cyano, lower alkyl, lower haloalkyl, cycloalkyl, lower alkoxy, lower haloalkoxy, or lower hydroxyalkyl group; R1 represents a lower alkyl group, a halogen atom, or a lower haloalkyl, cycloalkyl, cyano, or lower hydroxyalkyl group; and W represents a nitrogen atom or a methine group.] [In formula (7), R2 represents a lower alkyl, lower haloalkyl, cycloalkyl, lower alkenyl, or aralkyl group; and R3 represents a chlorine, bromine, or iodine atom.]
The present invention addresses the problem of providing a formulation having excellent pharmaceutical effects, in the context of pharmaceutical compositions for treatment of infections (e.g., vaginitis) which contains a compound represented by general formula (I) of claim 1. The present invention pertains to: a pharmaceutical composition containing a compound represented by general formula (I) of claim 1 and an excipient, and further containing one or more components selected from components A of claim 1; and a method for preparing a formulation containing the pharmaceutical composition.
Provided is a syringe for tympanic injection with which it is possible to reliably ascertain that the injection solution inside the syringe is within a temperature range suited to administration into the tympanum immediately before injection. The present invention is a syringe for tympanic injection 10 for injecting an injection solution inside a syringe 12 directly into the tympanum, wherein the syringe for tympanic injection 10 has first and second reversible temperature-indicating members 20, 25 provided on the outside surface 12b of the syringe, and visibly shows the injection temperature range suited to administration into the tympanum by the difference in the temperature at which the reversible temperature-indicating members 20, 25 change color. This makes it possible to visually confirm the temperature range of the injection solution suited to administration into the tympanum and to reliably ascertain that the injection solution inside the syringe 12 is within the temperature range suited to administration into the tympanum by the user of the syringe for tympanic injection 10 visually observing the reversible temperature-indicating members 20, 25 immediately before injection.
A compound having an URAT1 inhibitory activity, and an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, a compound represented by the formula (I):
3 or the like.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound.
More specifically, the present invention relates to a compound represented by the formula (I):
3 or the like.
C07D 221/02 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups condensed with carbocyclic rings or ring systems
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to: a compound which has URAT1 inhibitory activity; and a URAT1 inhibitor, a blood uric acid level reducing agent and a pharmaceutical composition, each of which contains the compound. The present invention more specifically relates to a compound represented by formula (I). (In the formula, R1 represents -Q1-A1 or the like; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or the like; each of W1, W2, W3 and W4 independently represents a nitrogen atom, an optionally substituted methine group or the like; each of X and Y represents a single bond, an oxygen atom or the like; and Z represents a hydroxyl group, COOR3 or the like.)
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/04 - Drugs for disorders of the urinary system for urolithiasis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to: a compound having a URAT1 inhibitory activity; and an URAT1 inhibitor, a blood uric acid level reducing agent and a pharmaceutical composition, each of which comprises the compound. More specifically, the present invention relates to a compound represented by formula (I). [In the formula, R1 represents -Q1-A1 or the like; AA represents a double bond or a single bond; W1 represents a nitrogen atom or a group represented by general formula: =C(Ra)- and W2 represents a nitrogen atom or a group represented by general formula: =C(Rb)- when AA represents a double bond; W1 represents a group represented by general formula: -C(Raa)(Rab)- or a group represented by general formula: -(C=O)- and W2 represents a group represented by general formula: -C(Rba)(Rbb)-, a group represented by general formula: -(C=O)- or a group represented by general formula: -N(Rbc)- when AA represents a single bond; W3, W4 and W5 independently represent a nitrogen atom, a methine group which may have a substituentor the like; X represents a single bond, an oxygen atom or the like; Y represents a single bond or (CRYiRYi')n; and Z represents a hydroxy group, COOR2 or the like.]
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/04 - Drugs for disorders of the urinary system for urolithiasis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
C07D 235/08 - Radicals containing only hydrogen and carbon atoms
C07D 235/10 - Radicals substituted by halogen atoms or nitro radicals
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention provides a disintegrating tablet which displays excellent disintegrating ability, strength and drug stability while containing a hygroscopic drug. Specifically, the present invention provides a disintegrating tablet comprising a drug having an equilibrium moisture content of 10-20% under a relative humidity of 75% at 25°C, erythritol, mannitol, and hydroxypropyl cellulose having an equilibrium moisture content of 5-20% under a relative humidity of 75% at 25°C and having a viscosity of 100-2000 cps when being in the form of an aqueous solution of 20% by mass at 37°C, wherein said disintegrating tablet contains said drug in an amount of 15-50% by mass of the total amount of said disintegrating tablet and has porosity of 10-40%.
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
The present invention relates to a film preparation having both rapid solubility and flexibility at the same time. The film preparation is characterized by comprising: an active-ingredient-containing layer comprising an active ingredient, a water-soluble polymer selected from the group consisting of methyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose, and a disintegrating agent; and an active-ingredient-free layer comprising methyl cellulose and/or hydroxypropyl methyl cellulose. It is further characterized in that the amount of the active ingredient is 0.1-75.0 mass % of a total mass of the film preparation and a total content of the active ingredient and the water-soluble polymer in the active-ingredient-containing layer is 15.0-95.0 mass % of a total mass of the active-ingredient-containing layer.
To obtain an injection needle for otological use which enables more accurate injection and diffusion of a drug within an extremely small area in the middle ear inside the tympanic membrane. An injection needle (10), which is to be used in stinging the tympanic membrane and thus injecting a drug into a cartilage located within the middle ear, having a needle length of from 40 to 60 mm, a cut angle (R) in the cut part (12) of 16o or below and a needle diameter (D) of 27 gauge or above. Owing to this structure, it is possible to more accurately inject a drug into a target site of a cartilage that is located within the middle ear inside the tympanic membrane. That is, the damage of the tympanic membrane can be minimized in the course of the passage of the needle through the tympanic membrane since the needle diameter and the cut angle are both reduced compared with the existing needles. Moreover, it is possible to relieve pain accompanied by the injection to an infant, etc.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A medicinal film preparation which reconciles rapidly dissolving properties with flexibility. The medicinal film preparation is characterized by comprising: an active-ingredient-containing layer comprising an active ingredient, a water-soluble polymer selected from the group consisting of methyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose, and a disintegrator; and an active-ingredient-free layer comprising methyl cellulose and/or hydroxypropyl methyl cellulose. It is further characterized in that the amount of the active ingredient is 0.1-75.0 mass% based on the whole medicinal film preparation and the sum of the active ingredient and the water-soluble polymer in the active-ingredient-containing layer is 15.0-95.0 mass% based on the whole active-ingredient-containing layer.
